Trial Profile

A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nerandomilast (Primary)
Indications Idiopathic pulmonary fibrosis
Focus Registrational; Therapeutic Use
Acronyms FIBRONEER™-IPF
Sponsors Boehringer Ingelheim

Most Recent Events

10 Jan 2025 Status changed from active, no longer recruiting to completed.
26 Sep 2024 Planned End Date changed from 15 Nov 2024 to 9 Dec 2024.
16 Sep 2024 According to Boehringer Ingelheim Media Release, Based on the results of this trial, Boehringer Ingelheim will submit the new drug application for nerandomilast for the treatment of IPF to the US Food & Drug Administration (FDA) and other Health Authorities worldwide.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com